Negligence in biomedical research: an anti-racist approach for substance use researchers.


Journal

Frontiers in public health
ISSN: 2296-2565
Titre abrégé: Front Public Health
Pays: Switzerland
ID NLM: 101616579

Informations de publication

Date de publication:
2024
Historique:
received: 14 03 2024
accepted: 15 07 2024
medline: 15 8 2024
pubmed: 15 8 2024
entrez: 15 8 2024
Statut: epublish

Résumé

Racism is embedded in the fabric of society at structural, disciplinary, hegemonic, and interpersonal levels, working as a mechanism that drives health disparities. In particular, stigmatized views of substance use get entangled with racialization, serving as a tool to uphold oppressive systems. While national health institutions have made commitments to dismantle these systems in the United States, anti-racism has not been integrated into biomedical research practice. The ways in which substance use researchers use and interpret race data-without engaging in structural racism as a mechanism of health inequity-can only be described as inadequate. Drawing upon concepts from the Public Health Critical Race praxis, QuantCrit, and an anti-racism research framework, we recommend a set of guidelines to help biomedical researchers conceptualize and engage with race more responsibly in substance use research.

Identifiants

pubmed: 39145167
doi: 10.3389/fpubh.2024.1401221
pmc: PMC11322128
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1401221

Informations de copyright

Copyright © 2024 Lehman, Balangoy, Mejia, Cardenas-Iniguez, Marek and Randolph.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Jonathan Lehman (J)

Masonic Institute for the Developing Brain, University of Minnesota, Minneapolis, MN, United States.

Danniella Balangoy (D)

Masonic Institute for the Developing Brain, University of Minnesota, Minneapolis, MN, United States.

Angie P Mejia (AP)

Masonic Institute for the Developing Brain, University of Minnesota, Minneapolis, MN, United States.

Carlos Cardenas-Iniguez (C)

Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA, United States.

Scott Marek (S)

Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, United States.
Neuroimaging Labs Research Center, Washington University School of Medicine, St. Louis, MO, United States.
Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, United States.
AI Institute for Health, Washington University School of Medicine, St. Louis, MO, United States.

Anita C Randolph (AC)

Masonic Institute for the Developing Brain, University of Minnesota, Minneapolis, MN, United States.
Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH